Soligenix Submits New Drug Application to FDA

Soligenix, Inc., (Nasdaq: SNGX), a late-stage biopharmaceutical company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for HyBryte™, a treatment for cutaneous T-cell lymphoma (CTCL).  Watch the video interview.  Soligenix estimates the potential worldwide market for HyBryte™ (synthetic hypericin) to be in excess of $250 million for the treatment of CTCL.

Highlights 

  • The submission of the NDA positions Soligenix to fulfill its promise to offer an innovative first-in-class therapy to CTCL patients.
  • HyBryte™ potentially represents the safest available efficacious treatment for CTCL, with very limited systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic.
  • Soligenix anticipates potential approval in the second half of 2023 and is targeting its U.S. launch in the first quarter of 2024.

CTCL is a rare, chronic cancer that is difficult to treat and remains an area of unmet medical need with a very limited number of safe and effective treatment options. It affects more than 25,000 individuals in the U.S., with approximately 3,000 new cases seen annually.

About the Author

Soligenix Submits New Drug Application to FDA

Editor Investors Prism